February 13, 2018 : DCMS #384

SPECIAL FEATURE

How Do Patients and HCPs Really Feel About CGMS?

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Ray Kausik Part 7, PCSK9 Inhibitor Side Effects

HOMERUN SLIDES — Great Clinical Presentation Highlights

Framework for Understanding DM Part 8

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #112: Diabetes and Sleep Apnea Part 2

MOST POPULAR ARTICLES OF THE MONTH

#1 Know Your Insulins, Teach Your Patient
#2 SGLT-2 Inhibitors Vs DPP-4 Inhibitors Vs. GLP1’s For Type 2 Diabetes
#3 A Summary of ADA’s New 2018 Standards of Medical Care in Diabetes

There seems to be a consensus amongst medical professionals and researchers that patients don’t want to test their glucose regardless of how bad their condition is.

It appears that CGMS is the future according to a lot of experts. But is it feasible in the real world?

This week, we have a CGMS survey from one of the most well-respected investment and management companies, taking a look at the practical use of this technology. Please take the time to complete this survey by clicking here.

Your answers may go a long way in making CGMS the standard of care.

Dave Joffe

Editor-in-chief

Both patients with diabetes and health care professionals expect wider adoption of continuous glucose management systems in the future for patients with type 2 as well as type 1, and agree that cost is a key factor in patient choices

In part 7, the conclusion of this Exclusive Interview, Dr. Ray Kausik talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 convention in San Diego, CA about the side effects so far of the new inhibitor drug and watching for reactions.

In this week’s Homerun Slides, the impact of diabetes medication on the heart and other organs, and the frequency of hypoglycemia.

OSA epidemiology and risk factors: The prevalence of OSA varies considerably between studies, mainly due to differences in the population studied, study designs, and the method and criteria used to diagnose OSA. A prevalence of 4% in men and 2% in women has traditionally been quoted in many populations. The prevalence from three well-conducted studies with similar design from Wisconsin, Pennsylvania, and Spain showed an OSA prevalence of 17–26% in men and 9–28% in women and a prevalence of 9–14% and 2–7% for men and women with moderate to severe OSA. These studies used a two-stage sampling design which allows some degree of estimate of the “self-selection” bias which is usually a significant problem in OSA studies.

Woman, 67 years of age, type 2 diabetes for 22 years, class II obesity. Has recently been managing her glucose levels with weight loss, using Tresiba, Trulicity, and metformin. Recent A1C 6.5%, which she’s worked hard for and been extremely proud of. She hasn’t had numbers like she has recently had for years.

How best to decide whether to use one or a combination of the new treatments and individualize the treatment for your patients.

Comprehensive recommendations feature notable new recommendations for people with cardiovascular disease and diabetes.